Login to Your Account

Pharmasset, Roche Sign HCV Agreement Worth Up To $300M

By Aaron Lorenzo

Thursday, October 28, 2004
Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription